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Mucopolysaccharidosis type IIIA (MPS-IIIA) is a neurodegenerative lysosomal storage disorder characterized 
by the deficiency of the enzyme sulfamidase. The pathology is characterized by different stages, each defined 
by a specific set of symptoms. The neurobiological mechanisms leading to these symptoms are still unknown. 
In the early phase, children with MPS-IIIA manifests with behavioural symptoms (BSs), including stereotypic 
and social behaviour dysfunctions; these symptoms are progressively substituted by the onset of dementia 
and motor impairment. Using an animal model of MPS-IIIA, we have identified endophenotypes of early and 
late stages of MPS-IIIA pathology, which are associated to dynamic changes in tyrosine hydroxylase (TH) 
expression, the dopamine (DA) synthesis-rating enzyme. This dynamic changes in TH expression are 
recapitulated in a cellular model of the pathology. These findings are important to define specific antipsychotic 
therapy for behavioral symptoms, and to understand the disease’ mechanisms leading to DA dysfunctions in 
MPS-IIIA. 
 
